Compare MOBX & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MOBX | NOTV |
|---|---|---|
| Founded | 2020 | 1974 |
| Country | United States | United States |
| Employees | 46 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 12.7M |
| IPO Year | N/A | 1997 |
| Metric | MOBX | NOTV |
|---|---|---|
| Price | $0.88 | $0.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | ★ 98.7M | 553.8K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 49.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $547,656,000.00 |
| Revenue This Year | N/A | $5.28 |
| Revenue Next Year | N/A | $5.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 511.19 |
| 52 Week Low | $0.13 | $0.25 |
| 52 Week High | $1.44 | $3.35 |
| Indicator | MOBX | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 65.73 | 57.99 |
| Support Level | $0.78 | $0.26 |
| Resistance Level | $0.92 | $0.65 |
| Average True Range (ATR) | 0.17 | 0.04 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 61.39 | 80.60 |
Mobix Labs Inc designs, develops and sells components and systems for wireless and wired connectivity, radio frequency (RF), switching and electromagnetic interference (EMI) filtering technologies. Its wireless systems solutions include products for RF and millimeter wave (mmWave) communications, mmWave imaging, software defined radio and custom RF integrated circuits (ICs) targeting the defense, aerospace, commercial and industrial sectors. The majority of the company's revenue is derived from product sales to equipment manufacturers. Geographically, it generates the maximum revenue from the United States.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.